Chinese consumer health market is growing fast. Western health businesses can have a sweet spot in China. Check out this insight article!
As another Australian Chinese healthcare commercialisation series, this time the Melbourne HealthCare Drinks event was held on Friday 23rd February, co-organised with ACASE.
China Food and Drug Administration (CFDA) was approved as a new regulatory member of the ICH. We analyse this milestone and its impact in this article.
The China regulator announced four new draft regulations on drugs and medical devices. What’s the impact on overseas companies? Find out in this article.
The draft regulation was approved by CFDA on 20–Jun-2017 and published on 11-Oct-2017, under the title of No. 35 CFDA Degree. There are only minor revisions compared to the original statements.
The China aged care sector: senile finance, supplies, services and real estate are all in infancy, with huge potential to grow. What are the aged care business opportunities in China for a Western business?